Financial Survey: Forward Pharma A/S (FWP) versus Galmed Pharmaceuticals (GLMD)

Forward Pharma A/S (NASDAQ: FWP) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

20.2% of Forward Pharma A/S shares are held by institutional investors. Comparatively, 17.3% of Galmed Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Forward Pharma A/S and Galmed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Forward Pharma A/S N/A N/A N/A
Galmed Pharmaceuticals -1,073.09% -110.46% -83.72%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Forward Pharma A/S and Galmed Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forward Pharma A/S 0 1 0 0 2.00
Galmed Pharmaceuticals 0 0 4 0 3.00

Forward Pharma A/S presently has a consensus target price of $6.00, suggesting a potential upside of 112.01%. Galmed Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 93.03%. Given Forward Pharma A/S’s higher possible upside, research analysts plainly believe Forward Pharma A/S is more favorable than Galmed Pharmaceuticals.

Earnings & Valuation

This table compares Forward Pharma A/S and Galmed Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forward Pharma A/S $1.25 billion 0.11 $917.09 million N/A N/A
Galmed Pharmaceuticals $1.09 million 227.49 -$12.29 million ($0.98) -16.39

Forward Pharma A/S has higher revenue and earnings than Galmed Pharmaceuticals.

Dividends

Forward Pharma A/S pays an annual dividend of $23.07 per share and has a dividend yield of 815.2%. Galmed Pharmaceuticals does not pay a dividend.

Risk and Volatility

Forward Pharma A/S has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500.

Summary

Forward Pharma A/S beats Galmed Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Forward Pharma A/S

Forward Pharma A/S operates as a biopharmaceutical company. The company focuses on developing FP187, a proprietary formulation of dimethyl fumarate, which has been completed Phase II clinical trials used for the treatment of various inflammatory and neurological indications, including multiple sclerosis and other immune disorders, such as psoriasis. Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply